Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2010

View Archived Issues

Suven Life Sciences presents new agents with encouraging in vivo procognitive activity

Auspex Pharmaceuticals claims deuterated SGLT-2 inhibitors

Abbott discloses new HCV serine protease NS3 inhibitors

Merck & Co. launches Dulera in U.S. for asthma

Results reported on Basilea's Toctino in severe chronic hand eczema

PAION advances phase IIb trial of anesthetic/sedative remimazolam

BrainStorm and Hadassah to begin phase I/II trial of NurOwn technology platform candidate in ALS

ACT submits response to FDA regarding phase I/II MA-09-HRPE trial in eye disease

Prolactin receptor expression is potential biomarker for colorectal cancer progression

Methylation state of HOXD3 gene identified as biomarker for prostate cancer

Promising preliminary phase II data disclosed on HIV immunotherapeutic AGS-004

Conatus Pharmaceuticals acquires Idun Pharmaceuticals from Pfizer

FDA confirms orphan drug exclusivity of Wilate for von Willebrand's disease

Astellas and Kotobuki disclose new SGLT-1 and SGLT-2 inhibitors

German scientists identify new HIF-1-alpha inhibitors

Dainippon Sumitomo Pharma presents new Na(V)1.8 channel inhibitors

Cardioxyl reports phase I/IIa data on CXL-1020 in heart failure

Servier to develop and commercialize Osteologix's NBS-101 outside U.S.

Repligen receives funds to develop HDAC inhibitors in Friedreich's ataxia and HD

FDA approves Xeomin for cervical dystonia and blepharospasm

Quest Diagnostics' XSense test for fragile X syndrome approved in New York state

ArQule and Daiichi Sankyo advance ARQ-197 to phase III in non-small cell lung cancer

BioMarin reports topline phase II data on PEG-PAL in PKU

BioMarin discontinues development of BMN-195

Reduced TSPO expression and low progesterone are linked to MDD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...